<p>隨着亞洲市場在強勁的企業盈利和韌性的經濟指標的推動下經歷增長期，投資者越來越關注那些內部持股比例較高的公司。在這種環境下，結合高內部持股和顯著預期盈利增長的股票，對於那些希望與對公司成功有切身利益的內部人士利益一致的投資者來説，可能會呈現出誘人的機會。</p>
<h3>亞洲內部持股比例高的十大成長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>19.1%</td>
<td>68%</td>
</tr>
<tr>
<td>蘇州三門科技 (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36%</td>
<td>25.8%</td>
</tr>
<tr>
<td>上海華測導航科技 (SZSE:300627)</td>
<td>24.3%</td>
<td>24.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 Technology (TPEX:6643)</td>
<td>30.8%</td>
<td>95.5%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>43%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>32.8%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>12.8%</td>
<td>43.7%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速增長的亞洲內部持股高的公司篩選器中的 593 只股票的完整列表。</p>
<p>讓我們探索篩選結果中的幾個突出選項。</p>
<h2>榮昌生物 (SEHK:9995)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 榮昌生物有限公司是一家生物製藥公司，專注於在中國大陸和美國發現、開發和商業化用於自身免疫、腫瘤和眼科疾病的生物製劑，市值約為港幣 401.4 億。</p>
<p><strong>運營：</strong> 榮昌生物的生物製藥研究、服務、生產和銷售收入約為人民幣 19.1 億元。</p>
<p><strong>內部持股：</strong> 11.2%</p>
<p><strong>盈利增長預測：</strong> 每年 66.3%。</p>
<p>榮昌生物正在經歷顯著增長，預計盈利每年增長 66.34%，收入預計每年增長 24.6%，超過香港市場。儘管股價波動較大，但其交易價格顯著低於估計的公允價值。最近的發展包括 RC148 在美國的臨牀試驗獲得 FDA 批准，以及 Telitacicept 的全球三期試驗，突顯其創新藥物管線和未來在國際市場擴展的潛力。</p>
<ul>
<li>解鎖我們對榮昌生物股票分析的全面見解，詳見本增長報告。</li>
<li>我們的全面估值報告提出榮昌生物的股價可能高於其財務狀況所能合理支持的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:9995 截至 2025 年 8 月的盈利和收入增長</p>
<h2>安徽壹石通材料科技有限公司 (SHSE:688733)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 安徽壹石通材料科技有限公司專注於鋰電池塗層、電子通信功能填充和低煙鹵素-free 阻燃材料，市值為人民幣 52.4 億元。</p>
<p><strong>運營：</strong> 該公司從其特種化學品部門產生的收入為人民幣 5.1072 億元。</p>
<p><strong>內部持股：</strong> 32.8%</p>
<p><strong>盈利增長預測：</strong> 每年 60.8%。</p>
<p>安徽壹石通材料科技有限公司預計將實現強勁擴張，預計盈利每年增長 60.8%，收入預計每年增長 23.7%，超過中國市場的增長率。該公司最近實現盈利，但面臨大型一次性項目對其財務結果的影響。儘管存在這些挑戰，最近幾個月沒有報告重大內部交易活動，表明內部人士對公司前景的情緒穩定。</p>
<ul>
<li>點擊這裏發現安徽壹石通材料科技有限公司的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們的估值報告揭示安徽壹石通材料科技有限公司的股票可能以溢價交易。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown"/></p>
<p>SHSE:688733 截至 2025 年 8 月的持股結構</p>
<h2>Caliway Biopharmaceuticals (TWSE:6919)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Caliway Biopharmaceuticals 有限公司及其子公司專注於開發用於美學醫學和慢性炎症的藥物，市值為新台幣 2086.1 億元。</p>
<p><strong>運營：</strong> Caliway Biopharmaceuticals 有限公司通過專注於美學醫學和慢性炎症的藥物開發產生收入。</p>
<p><strong>內部持股：</strong> 24.2%</p>
<p><strong>盈利增長預測：</strong> 每年 93.8%。</p>
<p>Caliway Biopharmaceuticals 正經歷顯著的增長潛力，預計收入每年增長 89%，超過台灣市場。該公司最近因被納入 MSCI 全球標準指數而獲得認可，並已啓動其創新藥物 CBL-514 的關鍵三期試驗。儘管股價波動較大且當前缺乏有意義的收入，Caliway 在臨牀開發中的戰略進展使其在未來三年內實現盈利的前景良好。</p>
<ul>
<li>點擊這裏深入瞭解 Caliway Biopharmaceuticals 的完整分析未來增長報告。</li>
<li>我們編制的估值報告表明 Caliway Biopharmaceuticals 當前的價格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:6919 截至 2025 年 8 月的盈利和收入增長</p>
<h2>關鍵要點</h2>
<ul>
<li>通過使用我們的篩選器，深入瞭解所有 593 家快速增長的亞洲內部持股高的公司。</li>
<li>對其他選項感到好奇？特朗普承諾將&#34;釋放&#34;美國的石油和天然氣，這 22 只美國股票的發展有望受益。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

壹石通

榮昌生物

<p>隨着亞洲市場的增長，投資者正關注那些內部持股比例高且盈利增長顯著的公司。值得注意的公司包括 Vuno（15.6% 的內部持股，109.8% 的盈利增長）、Techwing（19.1%，68%）和榮昌生物（11.2%，66.3%）。榮昌生物是一家生物製藥公司，正在通過 FDA 試驗和強勁的收入預測進行擴張。安徽壹石通材料科技（32.8%，60.8%）和 Caliway 生物製藥（24.2%，93.8%）也展現出良好的增長潛力。分析強調了亞洲成長股中內部持股的投資機會，突出了投資者與公司內部人士之間利益的一致性</p>

<p>As Asian markets experience a period of growth, bolstered by strong corporate earnings and resilient economic indicators, investors are increasingly focusing on companies with robust insider ownership. In this environment, stocks that combine high insider stakes with significant expected earnings growth can present compelling opportunities for those seeking to align their interests with company insiders who have a vested interest in the firm's success.</p>
<div class="lb-trans"><p>隨着亞洲市場在強勁的企業盈利和韌性的經濟指標的推動下經歷增長期，投資者越來越關注那些內部持股比例較高的公司。在這種環境下，結合高內部持股和顯著預期盈利增長的股票，對於那些希望與對公司成功有切身利益的內部人士利益一致的投資者來説，可能會呈現出誘人的機會。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亞洲內部持股比例高的十大成長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>19.1%</td>
<td>68%</td>
</tr>
<tr>
<td>Suzhou Sunmun Technology (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36%</td>
<td>25.8%</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology (SZSE:300627)</td>
<td>24.3%</td>
<td>24.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 Technology (TPEX:6643)</td>
<td>30.8%</td>
<td>95.5%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>43%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>32.8%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>12.8%</td>
<td>43.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>19.1%</td>
<td>68%</td>
</tr>
<tr>
<td>蘇州三門科技 (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36%</td>
<td>25.8%</td>
</tr>
<tr>
<td>上海華測導航科技 (SZSE:300627)</td>
<td>24.3%</td>
<td>24.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 Technology (TPEX:6643)</td>
<td>30.8%</td>
<td>95.5%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>43%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>32.8%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>12.8%</td>
<td>43.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 593 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速增長的亞洲內部持股高的公司篩選器中的 593 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>讓我們探索篩選結果中的幾個突出選項。</p>
</div><h2>RemeGen (SEHK:9995)</h2>
<div class="lb-trans"><h2>榮昌生物 (SEHK:9995)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$40.14 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 榮昌生物有限公司是一家生物製藥公司，專注於在中國大陸和美國發現、開發和商業化用於自身免疫、腫瘤和眼科疾病的生物製劑，市值約為港幣 401.4 億。</p>
</div><p><strong>Operations:</strong> RemeGen's revenue from biopharmaceutical research, service, production, and sales amounts to approximately CN¥1.91 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 榮昌生物的生物製藥研究、服務、生產和銷售收入約為人民幣 19.1 億元。</p>
</div><p><strong>Insider Ownership:</strong> 11.2%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 11.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 66.3% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 66.3%。</p>
</div><p>RemeGen is experiencing significant growth, with earnings forecasted to grow 66.34% annually and revenue expected to increase by 24.6% per year, outpacing the Hong Kong market. Despite high share price volatility, it trades at a notable discount below its estimated fair value. Recent developments include FDA clearance for clinical trials of RC148 in the US and a global Phase 3 trial for Telitacicept, highlighting its innovative drug pipeline and potential for future expansion in international markets.</p>
<div class="lb-trans"><p>榮昌生物正在經歷顯著增長，預計盈利每年增長 66.34%，收入預計每年增長 24.6%，超過香港市場。儘管股價波動較大，但其交易價格顯著低於估計的公允價值。最近的發展包括 RC148 在美國的臨牀試驗獲得 FDA 批准，以及 Telitacicept 的全球三期試驗，突顯其創新藥物管線和未來在國際市場擴展的潛力。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of RemeGen stock in this growth report.</li>
<li>Our comprehensive valuation report raises the possibility that RemeGen is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對榮昌生物股票分析的全面見解，詳見本增長報告。</li>
<li>我們的全面估值報告提出榮昌生物的股價可能高於其財務狀況所能合理支持的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:9995 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>SEHK:9995 截至 2025 年 8 月的盈利和收入增長</p>
</div><h2>Anhui Estone Materials TechnologyLtd (SHSE:688733)</h2>
<div class="lb-trans"><h2>安徽壹石通材料科技有限公司 (SHSE:688733)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Anhui Estone Materials Technology Co., Ltd specializes in lithium battery coating, electronic communication functional filling, and low-smoke halogen-free flame-retardant materials in China with a market cap of CN¥5.24 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 安徽壹石通材料科技有限公司專注於鋰電池塗層、電子通信功能填充和低煙鹵素-free 阻燃材料，市值為人民幣 52.4 億元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥510.72 million from its specialty chemicals segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其特種化學品部門產生的收入為人民幣 5.1072 億元。</p>
</div><p><strong>Insider Ownership:</strong> 32.8%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 32.8%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 60.8% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 60.8%。</p>
</div><p>Anhui Estone Materials Technology Ltd. is projected to see robust expansion, with earnings anticipated to grow 60.8% annually and revenue expected to rise by 23.7% per year, surpassing the Chinese market's growth rates. The company recently turned profitable but faces challenges from large one-off items affecting its financial results. Despite these hurdles, no substantial insider trading activity has been reported in recent months, indicating stability in insider sentiment toward the company's prospects.</p>
<div class="lb-trans"><p>安徽壹石通材料科技有限公司預計將實現強勁擴張，預計盈利每年增長 60.8%，收入預計每年增長 23.7%，超過中國市場的增長率。該公司最近實現盈利，但面臨大型一次性項目對其財務結果的影響。儘管存在這些挑戰，最近幾個月沒有報告重大內部交易活動，表明內部人士對公司前景的情緒穩定。</p>
</div><ul>
<li>Click here to discover the nuances of Anhui Estone Materials TechnologyLtd with our detailed analytical future growth report.</li>
<li>Our valuation report unveils the possibility Anhui Estone Materials TechnologyLtd's shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現安徽壹石通材料科技有限公司的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們的估值報告揭示安徽壹石通材料科技有限公司的股票可能以溢價交易。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown"/></p>
<p>SHSE:688733 Ownership Breakdown as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:688733 截至 2025 年 8 月的持股結構</p>
</div><h2>Caliway Biopharmaceuticals (TWSE:6919)</h2>
<div class="lb-trans"><h2>Caliway Biopharmaceuticals (TWSE:6919)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries focus on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$208.61 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Caliway Biopharmaceuticals 有限公司及其子公司專注於開發用於美學醫學和慢性炎症的藥物，市值為新台幣 2086.1 億元。</p>
</div><p><strong>Operations:</strong> Caliway Biopharmaceuticals Co., Ltd. generates revenue through its focus on drug development for aesthetic medicine and chronic inflammation.</p>
<div class="lb-trans"><p><strong>運營：</strong> Caliway Biopharmaceuticals 有限公司通過專注於美學醫學和慢性炎症的藥物開發產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 24.2%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 24.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 93.8% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 93.8%。</p>
</div><p>Caliway Biopharmaceuticals is experiencing significant growth potential, with revenue forecasted to grow at 89% annually, outpacing the Taiwanese market. The company recently gained recognition by being added to the MSCI Global Standard Index and has initiated pivotal Phase 3 trials for its innovative drug CBL-514. Despite a volatile share price and current lack of meaningful revenue, Caliway's strategic advancements in clinical development position it well for future profitability within three years.</p>
<div class="lb-trans"><p>Caliway Biopharmaceuticals 正經歷顯著的增長潛力，預計收入每年增長 89%，超過台灣市場。該公司最近因被納入 MSCI 全球標準指數而獲得認可，並已啓動其創新藥物 CBL-514 的關鍵三期試驗。儘管股價波動較大且當前缺乏有意義的收入，Caliway 在臨牀開發中的戰略進展使其在未來三年內實現盈利的前景良好。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Caliway Biopharmaceuticals.</li>
<li>The valuation report we've compiled suggests that Caliway Biopharmaceuticals' current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Caliway Biopharmaceuticals 的完整分析未來增長報告。</li>
<li>我們編制的估值報告表明 Caliway Biopharmaceuticals 當前的價格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:6919 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>TWSE:6919 截至 2025 年 8 月的盈利和收入增長</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Get an in-depth perspective on all 593 Fast Growing Asian Companies With High Insider Ownership by using our screener here.</li>
<li>Curious About Other Options? Trump has pledged to &#34;unleash&#34; American oil and gas and these 22 US stocks have developments that are poised to benefit.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過使用我們的篩選器，深入瞭解所有 593 家快速增長的亞洲內部持股高的公司。</li>
<li>對其他選項感到好奇？特朗普承諾將&#34;釋放&#34;美國的石油和天然氣，這 22 只美國股票的發展有望受益。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

亞洲成長股，內部持股預計收益增長可達 93%